GSS genetic signatures limited

Aug 25 (Reuters) - Genetic Signatures Ltd (GSS) : INFLUENZA B...

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Aug 25 (Reuters) - Genetic Signatures Ltd (GSS) :

    • INFLUENZA B DETECTION EXPECTED TO IMPACT ON QUARTER SALES
    • A UNDERTAKEN AN INVESTIGATION
    • WELL-ADVANCED IN RESOLVING THE ISSUE, WHICH IS SPECIFIC TO INFLUENZA B VIRUS
    • FOUND SEASON'S INFLUENZA B VIRUS IS NOT BEING CONSISTENTLY DETECTED IN A SMALL PROPORTION OF LOW VIRAL CONCENTRATION SAMPLES
    • AT THIS TIME, WE EXPECT FORECAST REVENUE TO BE ABOUT A$2 MILLION FOR Q1 FY2023
    • DETECTION OF INFLUENZA A VIRUS IS UNAFFECTED.
    • IN INTERIM, SALE OF GENETIC SIGNATURES EASYSCREEN™ RESPIRATORY PATHOGEN DETECTION KIT HAS BEEN IMPACTED DURING THIS CURRENT QUARTER
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
26.0¢
Change
-0.005(1.89%)
Mkt cap ! $59.05M
Open High Low Value Volume
26.0¢ 26.0¢ 26.0¢ $13.90K 53.47K

Buyers (Bids)

No. Vol. Price($)
2 14925 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 50000 1
View Market Depth
Last trade - 11.38am 18/09/2025 (20 minute delay) ?
GSS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.